[Treatment of combined carotid and cardiac disease]

Kirsten Krohg-Sørensen1, Per Snorre Lingaas, Steinar Solberg

  • 1Thoraxkirurgisk avdeling, Rikshospitalet, 0027 Oslo. kirsten.krohg-sorensen@rikshospitalet.no

Insights

Managing combined carotid and cardiac disease is complex. This study found similar stroke/death risks (5.4-8.7%) across different invasive treatment strategies for these conditions.

Area of Science:

  • Cardiovascular Surgery
  • Neurology
  • Interventional Cardiology

Background:

  • Optimal management for combined carotid artery stenosis and cardiac disease remains debated.
  • Current literature lacks studies with conservative treatment control groups and documentation of endovascular treatment roles.
  • This study presents a treatment strategy and outcomes for patients with concurrent carotid and cardiac conditions.

Purpose of the Study:

  • To evaluate the treatment strategy and outcomes for patients with combined carotid and cardiac disease.
  • To compare risks of stroke and death across different invasive management approaches.
  • To assess the role of endovascular treatment in this patient population.

Main Methods:

  • A retrospective analysis of 95 procedures in 81 patients from January 2001 to December 2003.
  • Patients were divided into three groups: invasive treatment for both conditions (Group A), invasive carotid treatment with conservative cardiac management (Group B), and invasive carotid treatment without diagnosed heart disease (Group C).
  • Postoperative stroke and death rates were recorded for all interventions.

Main Results:

  • Group A (combined invasive treatment) had a 5.4% stroke/death rate (1 stroke, 1 cardiac death).
  • Group B (invasive carotid, conservative cardiac) had an 8.7% stroke/death rate (1 fatal hemorrhage, 1 contralateral stroke).
  • Group C (carotid only) had no reported stroke or death events.

Conclusions:

  • The observed stroke/death rates (5.4-8.7%) are comparable to meta-analyses (7-9%) for combined carotid and cardiac disease treatment.
  • Effective management requires a multidisciplinary approach, considering all options (conservative, endovascular, surgical) to minimize cardiovascular risk.
  • The goal is to prevent death, stroke, and heart failure by optimizing treatment strategies and reducing complication rates in high-risk patients.
Abstract

Related Concept Videos

Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...